-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。当社の12ヶ月目標株価179ドルは、2027年のEBITDA予測にEV/EBITDA倍率19.0倍を適用したものであり、ATIの過去12ヶ月間の平均予想EV/EBITDA倍率17.4倍を上回りますが、同業他社の平均予想EV/EBITDA倍率27.2倍を下回ります。2026年のEPS予想を0.03ドル引き上げて4.46ドルに、2027年のEPS予想を0.11ドル引き上げて5.51ドルとします。投資判断は、ファンダメンタルズの悪化ではなく、株価収益率の上昇を理由に「強力買い」から「買い」に引き下げます。ATIは、高付加価値の航空宇宙、防衛、特殊エネルギー市場を優先するという戦略を順調に実行しています。 ATIは2026年度通期業績見通しを引き上げ、調整後EBITDAは10億1,000万ドル～10億6,000万ドル（中間値で3,500万ドル増）となり、前年比20%増となる見込みです。過去最高の受注残高41億ドルとリードタイムの延長（ニッケル合金は1年以上、高級チタンは2年近く）により、見通しは良好です。経営陣は、連結EBITDAマージンが20%を超え、構成比の好調と長期契約価格により40%のマージン増が見込まれると予想しています。生産能力が制約されている市場におけるATIの差別化された地位は、当社の強気の見方を裏付けています。
Related Articles
Sectors
Update: Gold Falls as the Dollar and Yields Climb
(Updates prices.)Gold traded lower midafternoon Monday as the dollar and yields rose, forcing the precious metal below the tight range it has stuck within for the past month.Gold for June delivery was last seen down US$112.20 to US$4,533.20 per ounce, the lowest since March 27.The war on Iran has prompted some safe-haven demand for the metal, even as the higher oil prices that followed the start of the war on Iran is hiking inflation. This is raising concerns higher interest rates are on the way, which is bearish for the metal since it pays no interest."Gold remains supported by safe-haven demand as investors continue to watch the Middle East conflict, oil prices, and the yen. Any durable easing in the Strait of Hormuz would likely cool demand for defensive assets, but until shipping flows normalise, gold should remain sensitive to geopolitical headlines and shifts in real yields," Saxo Bank noted.The dollar rose, with the ICE dollar index last seen up 0.2.9 points to 98.45. Treasury yields were sharply higher, with the U.S. two-year note last seen paying 3.975%, up 8.3 basis points, while the yield on the 10-year note as up 7.0 points to 4.449%
$GCM6$GLD
Australia
Top Midday Gainers
Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria-1 trial, with the study meeting its primary endpoint and showing a clinically meaningful improvement in progression-free survival.The study evaluated gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer who had progressed after a CDK4/6 inhibitor and an aromatase inhibitor.Shares jumped more than 16%, with intraday trading volume at over 2.5 million from a daily average of roughly 737,000.CNS Pharmaceuticals (CNSP) shares surged 268% amid heavy trading after the company said Monday it signed deals for a private placement financing likely to generate roughly $22.5 million.Intraday trading volume catapulted to over 78.4 million shares from a daily average of about 32,000.American Express Global Business Travel, which is operated by Global Business Travel Group (GBTG), said Monday it has entered into a definitive agreement to be acquired by Long Lake Management for $9.50 per share in an all-cash deal valued at about $6.3 billion.Shares soared 57%, with intraday trading volume of over 61.6 million from a daily average of about 1.6 million.Price: $146.00, Change: $+20.35, Percent Change: +16.20%
$CELC$CNSP$GBTG
Sectors
Sector Update: Health Care Stocks Softer in Afternoon Trading
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.
$AMGN$LLY$MRNA$VNDA